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Stress cardiomyopathy (SCM) is a unique cardiac disorder that more often occurs in 
women. SCM presents in a similar fashion as acute myocardial infarction (AMI), with 
chest pain, ECG changes, and congestive heart failure. The primary distinguishing 
feature is the absence of thrombotic coronary occlusion in SCM. How this reduction 
in cardiac function occurs in the absence of coronary occlusion remains unknown. 
Therefore, we tested the hypothesis that a targeted proteomic comparison of patients 
with acute SCM and AMI might identify relevant mechanistic differences. Blood was 
drawn in normal controls (n = 6), women with AMI (n = 12), or women with acute SCM 
(n = 15). Two-week follow-up samples were available in AMI (n = 4) and SCM patients 
(n = 11). Relative concentrations of 1,310 serum proteins were measured in each of 
the 48 samples using the SOMAscan assay. Women with AMI had greater myocyte 
necrosis, as reflected by a higher peak troponin I concentration (AMI 32.03 ± 29.46 vs. 
SCM 2.68 ± 2.6 ng/ml, p < 0.05). AMI and SCM patients had equivalent reductions in 
left ventricular ejection fraction [LVEF (%) 39 ± 12 vs. 37 ± 12, p = 0.479]. In follow-up, 
women with SCM had a greater improvement in cardiac function [LVEF (%) 60 ± 7 vs. 
45 ± 13, p < 0.001]. No differentially expressed proteins were detected (absolute log2-
fold change >1; q <  0.05) between AMI and SCM in the acute or recovery phase. 
However, when we compared normal controls to patients with AMI, there was differential 
expression of 35 proteins. When we compared normal controls to patients with SCM, 
45 proteins were differentially expressed. In comparison to normal controls, biological 
processes such as complement, coagulation, and inflammation were activated in both 
AMI and SCM. There were four proteins that showed a non-significant trend to be 
increased in acute SCM vs. AMI (netrin-1, follistatin-like 3, kallikrein 7, kynureninase). 
Despite a lesser degree of myocardial necrosis than AMI, SCM is characterized by a 
similar activation of inflammatory, complement, and coagulation pathways. These find-
ings may explain reported thromboembolic complications in the short term and elevated 
risk of mortality in the long term of SCM.
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inTrODUcTiOn
Stress cardiomyopathy (SCM) is a unique form of heart disease 
that primarily affects women. Described in 1990 by Sato and 
colleagues, it is now recognized as accounting for 5.9–7.5% of 
women presenting to the emergency department with acute 
coronary syndromes (1–4). Although the prognosis is typically 
good, complications such as heart failure, arrhythmias, and 
thromboembolic phenomena do occur (5). Recent studies have 
shown that SCM patients have increased long-term morbid-
ity and mortality (5.6% risk of death per patient year) (6–8). 
Therefore, this disorder may not be as benign as previously 
thought.
After almost 30  years of study, the mechanism of SCM is 
still not understood. Plasma concentrations of norepinephrine, 
epinephrine, and dopamine are twofold higher than those of 
AMI (9). Myocardial biopsy in SCM reveals inflammation 
and myocyte contraction band necrosis, which are features of 
catecholamine excess (9). In contrast, acute myocardial infarc-
tion (AMI) has greater myocyte necrosis (10). Despite these 
different mechanisms of injury, cardiac function is impaired to 
an equivalent degree in both conditions (11). The exact mecha-
nism by which LV dysfunction occurs in SCM remains poorly 
understood.
Due to the presenting signs and symptoms, patients with SCM 
are referred for urgent coronary angiography, which reveals the 
absence of atherosclerotic plaque rupture. Coronary angiography 
exposes the SCM patient to unnecessary risk without therapeutic 
benefit. A biomarker that could differentiate between AMI and 
SCM would be useful, allowing for the identification of low risk 
SCM patients in whom angiography could be avoided. This 
would be especially helpful in patients with “secondary” SCM 
(5). “Secondary SCM” frequently occurs in medical intensive care 
units and is precipitated by critical illnesses such as sepsis (12). 
Due to the severity of illness in these cases, cardiac interventions 
such as coronary angiography or the initiation of antiplatelet 
therapy are often deferred.
There have been no studies examining novel protein bio-
markers in SCM. A ratio of serum B-type natriuretic peptide to 
troponin I (TnI) ≥1,272 is highly specific for SCM (95%) but has 
limited sensitivity (52%) (13). Soluble suppression of tumori-
genicity 2 has been studied to identify SCM in medical intensive 
care units (12). A circulating profile of plasma microRNAs 
(miR-16, mir-26a, miR-1, and miR-133a) has shown good sen-
sitivity and specificity for SCM (14). However, the use of plasma 
microRNAs for diagnostic purposes has not been adopted in 
clinical practice (15). Furthermore, these studies shed no light 
into the biologic differences between these two syndromes.
We hypothesized that there would be differences between 
circulating proteins in SCM and AMI that might elucidate the 
underlying mechanisms. Therefore, the purpose of our study was 
twofold. The first aim was to perform an unbiased comparison of 
circulating proteins in SCM and AMI in order to provide insight 
into the pathophysiology of SCM. Our second aim was to identify 
putative protein biomarkers of SCM.
In order to achieve these aims, we utilized recently described 
DNA aptamer technology to perform our screen (SOMAscan 
V1.3K, SOMAlogics) (16–18). This assay uses single stranded 
DNA aptamers to specifically bind 1,310 predetermined proteins 
in a single sample. The advantages of this technology include 
higher throughput and precision than traditional proteomic 
methods such as mass spectrometry or antibody based methods 
(16, 17).
Using this assay, we found that women presenting with either 
SCM or AMI have an increase in proteins related to complement, 
coagulation, and inflammation. The unexpected and profound 
activation of inflammatory and pro-thrombotic pathways in SCM 
may contribute to the increased risk of mortality attributed to this 
disorder (7, 8).
MaTerials anD MeThODs
Patient enrollment
Women who presented with non-ST or ST elevation myocardial 
infarction and had coronary angiography demonstrating either 
culprit LAD disease or apical variant SCM were prospectively 
enrolled. Detailed presenting features of the AMI group are 
shown in Table 1. We specifically limited our study to patients 
with culprit LAD disease and apical SCM in order to control for 
the differences between echocardiograms and clinical features 
that have been demonstrated with variants of SCM (19). All of 
the SCM patients met the Mayo Clinic Criteria for SCM (20). The 
normal control group for proteomic analyses consisted of 6 sub-
jects (3 females, 3 males) with a mean age of 51.33 ± 10.11 years. 
They were healthy ambulatory persons without diabetes, hyper-
lipidemia, hypertension, or known coronary disease and taking 
no prescription medications. Written informed consent was 
obtained according to protocol #00000941 as approved by the 
University of Massachusetts Medical School IRB.
serum isolation and Proteomic analysis
Non-fasting venous blood was drawn (after cardiac catheteriza-
tion but within 24 h of presentation) into SST tubes, spun, and 
frozen at −80°C. Acute samples were analyzed in 12 AMI patients 
and 15 SCM patients. Follow-up samples were drawn in clinic at 
2 weeks follow-up (AMI n = 4, SCM n = 11). We chose to sample 
blood at 2 weeks follow-up because this is the median time to 
recovery of LV function in SCM (9). Samples were shipped to an 
outside laboratory on dry ice where assays were performed using 
SOMAscan reagents according to the manufacturer’s protocol 
(16). The menu of the 1,310 protein aptamers included in the 
assay is available online.1 The median intra-assay and inter-assay 
coefficient of variation was 2.1%.
echocardiography
Complete 2D echocardiograms were performed within 24 h of 
presentation and in follow-up (2 weeks) in patients with AMI and 
SCM. Ejection fraction, 2D volumes, and linear dimensions were 
measured according to ASE guidelines (21).
1 http://www.somalogic.com/Technology/SOMAscan-basic-info/.
TaBle 1 | Angiographic characteristics of acute myocardial infarction group.
Patient culprit lesion Flow Presentation Onset of pain (h) Peak troponin i (ng/ml) Treatment
1 100% pLAD TIMI 0 STEMI 10 90.0 1 DES
2 90% pLAD ulcerated NSTEMI 1.84 1 DES
3 95% mLAD ulcerated TIMI 3 STEMI >48 33.7 2 DES
4 pLAD dissection TIMI 3 STEMI 4 20.2 None
5 pLAD 40%, possible spasm TIMI 3 NSTEMI 10 10.8 None
6 pLAD 80%, hazy TIMI 3 NSTEMI 2 1.21 1 DES
7 pLAD 80% TIMI 2 NSTEMI 13.8 1 DES
8 D1, 95% TIMI 2 STEMI 4 35.7 POBA D1
9 pLAD 99%, thrombus TIMI3 STEMI >48 70.0 1 DES
10 pLAD 99%, thrombus STEMI 10 13.0 1 DES
11 pLAD 95% TIMI 2 STEMI >48 8.0 1 DES
12 pLAD 95%, hazy STEMI 1 70.0 1 DES
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statistical Methods
Somalogics SOMAScan technology was used to measure levels 
of 1,310 predetermined proteins included in the assay (see text 
footnote 1) in 48 patient samples using 1,310. Protein expression 
levels were expressed as normalized counts [relative fluorescent 
units (RFUs)] for the 48 patient samples. Data were analyzed 
using Somalogics’ SomaSuite software (version 1.0.3a). The non-
parametric two-sided Mann–Whitney U-test was used to analyze 
the normalized expression levels, to determine statistically 
significant differentially expressed proteins for each pairwise 
group comparison. The p-value, q-value, and other statistics were 
calculated for each protein. The q-values are calculated using 
the false discovery rate (FDR) method (22). The fold change 
values for each pairwise comparison are computed on the aver-
age values in the log2 scale. Statistically differentially expressed 
proteins were defined if the following criteria are met (absolute 
log2-fold change >1; q < 0.05). The raw data for this study were 
deposited in the Gene Expression Omnibus and can be down-
loaded at https://www.ncbi.nlm.nih.gov/geo/info/linking.html  
(Accession GSE95368).
In order to determine signaling pathways altered in each 
condition, functional enrichment analysis was carried out using 
the WEB-based GEne SeT AnaLysis Toolkit (Webgestalt) (23). 
The Kyoto Encyclopedia of Genes and Genomes database was 
selected for enrichment analysis, with the proteome selected 
as the reference set. The hypergeometric test was used for 
enrichment evaluation for the lists of statistically differentially 
expressed proteins. The Benjamini and Hochberg method was 
used to calculate the adjusted p-values (q) and the significance 
cutoff filter was set to q < 0.05 (24).
The complex heatmap package (version 1.12.0) was used to 
generate a heatmap (Figure  1) and the following parameters 
were used (clustering distance rows =  “maximum,” clustering 
method rows = “ward.D”) (25). By determining if a protein was 
differentially expressed in one or more of the 10 possible com-
parisons (Figure 1), a list of proteins of interest was curated. This 
list comprising 64 proteins, together with the protein expression 
levels averaged for each protein in each of the medical condi-
tions, was used as input to generate a heatmap. Five clusters 
are generated; for each cluster, the members were identified 
(Figure 1).
resUlTs
clinical characteristics
The baseline clinical and echocardiographic characteristics 
are shown in Tables  1–3. Compared to AMI, women with 
SCM had lower systolic and diastolic blood pressure on 
admission (112.2 ±  16.5 vs. 126.3 ±  21.9 and 66.4 ±  12.1 vs. 
74.8 ±  11.6  mm  Hg, p <  0.05 for both). Left ventricular end 
diastolic pressure was elevated in both groups (18.7 ±  9.4 vs. 
14.9 ±  14.3  mm  Hg, p =  0.36). Women with AMI had higher 
peak values of TnI (32.03 ± 29.46 vs. 2.68 ± 2.6 ng/ml, p < 0.05) 
and CPK (1,206 ± 1,348 vs. 104 ± 63.5 ng/ml, p < 0.05) during 
their hospitalization.
echocardiographic characteristics
Stress cardiomyopathy and AMI patients had equivalent 
reductions in systolic function [LVEF (%)] in the acute phase 
(37 ±  12 vs. 39 ±  12, p =  0.47) (Table  3). However, SCM 
patients had smaller indexed left ventricular systolic (LVESVI 
24.41 ± 7.56 vs. 32.34 ± 13.54 ml/m2, p < 0.001) and diastolic 
(LVEDVI 45.53 ± 13.60 vs. 54.50 ± 13.63 ml/m2, p < 0.001) 
volumes than AMI. SCM patients also had a greater indexed 
left atrial volume than AMI (LAVI 33.1 ± 7.7 vs. 27.25 ± 6.0, 
p < 0.05).
Stress cardiomyopathy patients had a significantly greater 
improvement in LV systolic function in follow-up, as shown by the 
mean LVEF (%) (60 ± 7 vs. 45 ± 13, p < 0.001), interval change in 
ΔLVEF (%) (+23 ± 12 vs. +8 ± 13, p < 0.001), and interval reduc-
tion in LVESVI (ΔLVESVI −4.95 ± 9.7 vs. +2.0 ± 13.19 ml/m2, 
p < 0.05).
Proteomic analyses
There were no proteins differentially expressed (absolute log2-
fold change >1; q < 0.05) between AMI and SCM in the acute 
phase (Table 4). This was true even when we lowered the thresh-
old for differential regulation to q < 0.05 with any fold change 
(Table 4). When we compared normal controls vs. AMI, there 
were 35 proteins with differential expression (absolute log2-fold 
change >1; q < 0.05) (Figure 1; Table 4). In the normal vs. SCM 
comparison, 45 proteins were differentially regulated (absolute 
log2-fold change >1; q < 0.05) (Figure 1; Table 4).
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FigUre 1 | The heatmap shows the serum protein expression in the five groups [normal, the acute myocardial infarction conditions (AMI, AMI_Post) and the stress 
cardiomyopathy conditions (SCM, SCM_Post)]. By determining if a protein was differentially expressed in one or more of the ten possible comparisons, a list of 64 
proteins was generated. Differentially regulated proteins were defined using the following filters (absolute log2 fold change >1; q < 0.05). The average level of each 
protein, in each of these conditions, was used to generate the heat-map. Bright red is increased expression, and deep purple is decreased expression (Z-score). For 
example, concentrations of N-terminal pro-BNP (cluster 3) are increased in AMI and SCM compared to normal.
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Most of the proteins were commonly differentially regulated in 
both SCM and AMI compared to controls [Figure 1 (cluster 4), 
Figure 2; Table 5]. However, there were four candidate proteins 
that tended to be increased in acute SCM compared to AMI and 
controls. These proteins were kynureninase (KYNU), K7, follista-
tin-like 3, and netrin-1 (NET1) [Figure 1 (cluster 3); Table 5].
The heat map (Figure 1) and bar plots of significantly altered 
proteins (Figures S1 and S2 in Supplementary Material) demon-
strated the expected rise and fall of traditional markers of necrosis 
(TNNI3, CK-MB), inflammation (CRP), and wall stress (NPPB) 
in the acute and follow-up phase. There was a strong positive 
correlation between the hospital laboratory measured peak TnI 
TaBle 3 | Acute and recovery echocardiographic data.
acute myocardial 
infarction (n = 11)
stress 
cardiomyopathy 
(n = 15)
p-Value
Mean ± sD Mean ± sD
acute
EF (%) 39 ± 12 37 ± 12 0.479
LAVI (ml/m2) 33.1 ± 7.1 27.25 ± 6.0 <0.05
LVMI (gm/m2) 81.55 ± 19.0 82.95 ± 21.0 0.53
RWT 0.38 ± 0.04 0.41 ± 0.06 0.51
LVIDd (mm) 47.45 ± 5.99 45.58 ± 6.54 0.234
LVIDs (mm) 34.11 ± 7.27 30.05 ± 7.06 <0.05
LVEDV (ml) 95.15 ± 25.67 77.11 ± 23.70 <0.001
LVESV (ml) 56.73 ± 25.19 43.17 ± 12.94 <0.01
LVEDVI (ml/m2) 54.50 ± 13.63 45.53 ± 13.60 <0.001
LVESVI (ml/m2) 32.34 ± 13.54 24.41 ± 7.56 <0.001
recovery
EF (%) 45 ± 13 60 ± 7 <0.001
ΔEF (%) +8 ± 13 +23 ± 12 <0.001
LVIDd (mm) 49.91 ± 7.73 45.50 ± 5.58 <0.05
ΔLVIDd (mm) +1.40 ± 8.11 −0.21 ± 6.61 0.450
LVIDs (mm) 35.18 ± 8.30 27.68 ± 4.82 <0.001
ΔLVIDs (mm) −1.37 ± 7.46 −2.54 ± 5.17 0.529
LVEDV (ml) 99.88 ± 36.93 75.50 ± 18.93 <0.001
ΔLVEDV (ml) +5.77 ± 26.9 −3.20 ± 25.40 0.320
LVESV (ml) 58.82 ± 34.09 34.81 ± 13.67 <0.001
ΔLVESV (ml) +1.25 ± 13.34 −10.60 ± 15.70 <0.05
LVEDVI (ml/m2) 57.38 ± 18.57 45.50 ± 11.28 <0.001
ΔLVEDVI (ml/m2) +1.71 ± 15.38 −0.32 ± 14.03 0.917
LVESVI (ml/m2) 33.43 ± 17.87 19.63 ± 7.17 <0.001
ΔLVESVI (ml/m2) +2.03 ± 13.19 −4.95 ± 9.7 <0.05
EF, ejection fraction; LAVI, left atrial volume index; LVMI, left ventricular mass index; 
RWT, relative wall thickness; LVIDd, left ventricular internal dimension diastolic; LVIDs, 
left ventricular internal dimension systolic; LVEDV, left ventricular end diastolic volume; 
LVESV, left ventricular end systolic volume; LVEDVI, left ventricular end diastolic volume 
index; LVESVI, left ventricular end systolic volume index; ΔEF (%), change in ejection 
fraction; ΔLVIDd, change in left ventricular internal dimension diastolic; ΔLVIDs, change 
in left ventricular internal dimension systolic; ΔLVEDV, change in left ventricular end 
diastolic volume; ΔLVESV, change in left ventricular end systolic volume; ΔLVEDVI, 
change in left ventricular end diastolic volume index; ΔLVESVI, change in left ventricular 
end systolic volume index.
Values are mean ± SD or n (%). Italicized p values are statistically significant.
TaBle 2 | Clinical characteristics of study participants.
acute 
myocardial 
infarction 
(n = 16)
stress 
cardiomyopathy 
(n = 26)
p-Value
Age (years) 57.87 ± 16.0 65.08 ± 9.11 0.12
Height (cm) 158.2 ± 5.8 162.1 ± 6.5 0.06
Weight (kg) 72.3 ± 16.2 72.8 ± 11.6 0.90
BSA (m2) 1.7 ± 0.1 1.7 ± 0.14 0.55
Presenting HR (bpm) 80.3 ± 15.9 84.1 ± 14.1 0.43
Presenting SBP (mm Hg) 126.3 ± 21.9 112.2 ± 16.5 <0.05
Presenting DBP (mm Hg) 74.8 ± 11.6 66.4 ± 12.1 <0.05
HDL (mg/dl) 55.2 ± 36.6 61.3 ± 25.8 0.57
Total cholesterol (mg/dl) 182.4 ± 50.1 172.7 ± 40.8 0.54
LDL (mg/dl) 108.5 ± 44.2 92.5 ± 32.2 0.23
Peak troponin (ng/ml) 32.0 ± 29.4 2.6 ± 2.6 <0.05
Peak CPK (ng/ml) 1,206.0 ± 1,348 104.5 ± 63.5 <0.05
LVEDP (mm Hg) 14.9 ± 14.3 18.7 ± 9.4 0.36
Emotional stress trigger 0 (0%) 13 (52%) <0.001
Chest pain 14 (93%) 21 (84%) 0.388
Shortness of breath 6 (40%) 11 (44%) 0.804
Syncope 0 (0%) 2 (8%) 0.261
Rales 3 (20%) 0 (0%) <0.05
JVD 2 (13%) 0 (0%) 0.061
S3 or S4 1 (7%) 0 (0%) 0.191
Peripheral edema 4 (27%) 2 (8%) 0.109
Beta blockers 3 (25%) 8 (32%) 0.411
Calcium channel blockers 1 (7%) 5 (20%) 0.253
ACEi/ARBs 3 (25%) 11 (44%) 0.123
Diuretics 3 (25%) 6 (24%) 0.769
Statins 1 (7%) 11 (44%) <0.05
ASA 4 (27%) 9 (36%) 0.542
SSRI 3 (18%) 9 (34%) 0.282
Hypertension 6 (40%) 17 (68%) 0.083
Diabetes mellitus 3 (25%) 5 (20%) 0.281
Smoking history 8 (53%) 8 (32%) 0.182
Depression/anxiety 6 (40%) 14 (56%) 0.327
BSA, body surface area; HR, heart rate; SBP, systolic blood pressure; DBP, diastolic 
blood pressure; HDL, high-density lipoprotein; LDL, low-density lipoprotein; CPK, 
creatinine phosphokinase; LVEDP, left ventricular end-diastolic pressure; JVD, jugular 
venous distension; S3 or S4, third or fourth heart sound, respectively; ACEi/ARB, 
angiotensin converting enzyme inhibitor/angiotensin receptor blocker; ASA, aspirin; 
SSRI, selective serotonin reuptake inhibitor.
Values are mean ± SD or n (%). Italicized p values are statistically significant.
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(nanogram per milliliter) and the SOMAscan measured TnI 
(RFU) (ρ = 0.79, p < 0.001) (Figure 3).
Pathway analysis of the differentially regulated proteins in 
each group revealed a large degree of similarity (Tables  6 and 
7). The complement and coagulation pathway displayed the 
greatest enrichment ratio in both groups (Tables 6 and 7). There 
was significant overlap among other inflammatory pathways, 
nine of which were commonly increased in SCM and AMI. 
Several pathways were unique to SCM: focal adhesion, extracel-
lular matrix–receptor interaction, malaria, regulation of actin 
cytoskeleton, arrythmogenic right ventricular cardiomyopathy, 
axon guidance, and Wnt signaling (Table 7).
DiscUssiOn
Although the pathophysiology, natural history, and outcomes 
of AMI and SCM are different, they do share common features. 
First, both are characterized by acutely decreased cardiac func-
tion (11). Second, each condition can be complicated by heart 
failure, arrhythmia, or thromboembolic events. Due to these 
similarities, women presenting with SCM are often referred for 
coronary angiography (5). However, in low risk cases, and in 
cases of “secondary SCM,” a biomarker would be useful. One of 
the aims of our study was to discover putative biomarkers of SCM; 
we identified four candidates (FSTL3, Kallikrein7, KYNU, and 
NET1). A second aim was to learn about the pathophysiology of 
SCM by comparing serum proteins to normal patients and those 
with AMI. We were surprised to find no differences between SCM 
and AMI in the acute phase. Both conditions were characterized 
by a robust increase in proteins related to inflammation, coagula-
tion, and complement.
The characteristics of both study groups were consistent with 
prior studies. Patients with AMI had a greater peak TnI and a 
lower LVEF (%) on follow-up (7, 9, 11). SCM patients had smaller 
indexed LV diastolic and systolic volumes in both the acute and 
TaBle 5 | Specific proteins from Venn diagram subsection.
Venn diagram segment Proteins
2 proteins exclusively in acute myocardial 
infarction (AMI) vs. normal
HAMP, FGG
6 proteins exclusively in stress cardiomyopathy 
(SCM) vs. normal
C3, F5, FSTL3, Netrin-1, PLAT, 
THBS2
12 proteins exclusively in SCM  
post vs. normal
PGD, MYC, CTSD, GRB2, 
HIST2H2BE, HIST1H3A, IL9, 
JAK2, Kynureninase, MST1, 
SERPINA5, PIK3CA/PIK3R1
1 protein exclusively in AMI vs.  
SCM post
HPX
7 common proteins in AMI vs. normal and 
SCM vs. normal
NAMPT, F9, F9ab, HGF, GDF-
15, ITGA1/ITGB1, MBL2
1 common protein in SCM post vs. normal  
and AMI vs. SCM post
KLK7
3 common proteins in AMI vs. normal and 
SCM post vs. normal
XPNPEP1, PTPN6, CRYZL1
21 common elements in AMI vs. normal,  
SCM vs. normal and SCM post vs. normal
C3, LTA4H, C3a, iC3b, APOB, 
IL36A, C4A/C4B, ALB, EHMT2, 
MFGE8, F2, A2M, PRKACA, 
KLK3, RXFP1, APOE4, APOE3, 
PKM2, APOE, GAPDH, NPPB
9 common elements in SCM vs. normal  
and SCM post vs. normal
ARTN, AZU1, CA13, ELANE, 
FABP3, FTCD, ITGA2B/ITGB3, 
HNRNPK, SFRP1
2 common elements in AMI vs. normal,  
SCM vs. normal, and AMI vs. SCM post
CRP, TNNI3
FigUre 2 | Venn diagram showing differential and overlapping protein 
expression between the conditions compared (Table 4). As shown in the 
middle of the diagram, 30 (7+21+2) proteins are commonly differentially 
regulated in AMI and SCM compared to normal controls. Specific proteins 
from Venn diagram subsections are listed in Table 5.
TaBle 4 | Number of differentially expressed (DE) proteins between pairwise comparisons.
conditions compared number of De 
proteins with q < 0.05 
(absolute log2-fold 
change ignored)
number of De proteins 
with absolute log2-fold 
change >1; q < 0.05
number of De proteins with 
absolute log2-fold change 
>1; q < 0.05
number of De proteins with 
absolute log2-fold change  
>1; q < 0.05
Downregulated in condition 1 Upregulated in condition 1
Normal vs. acute myocardial infarction (AMI) 98 35 17 18
AMI vs. AMI post 0 0 0 0
Normal vs. AMI post 0 0 0 0
Normal vs. stress cardiomyopathy (SCM) 124 45 22 23
SCM vs. SCM post 0 0 0 0
Normal vs. SCM post 159 46 17 29
AMI vs. SCM 0 0 0 0
AMI vs. SCM post 40 4 1 3
SCM vs. AMI post 0 0 0 0
AMI post vs. SCM post 0 0 0 0
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recovery phase. SCM patients had normalization of their systolic 
function in recovery, as demonstrated by a greater increase in 
LVEF (%) (Table 2).
In regards to our proteomic analysis, we wish to emphasize 
that the SOMAscan 1.3  K measures a predetermined panel of 
1,310 proteins, which is only 6.5% of the approximately 20,000 
protein encoding genes in the genome. Therefore, there are many 
changes that were undetected by our assay. For example, tissue 
inhibitor of metalloproteinase 4 has previously been shown to 
be increased in SCM compared to AMI (26). However, tissue 
inhibitor of matrix metalloproteinase (TIMP)-4 specific aptamers 
were not included in the version of the SOMAscan that we used; 
therefore, this difference was not detected. Of the proteins that 
were included, many were commonly elevated in both AMI and 
SCM, particularly those related to complement, coagulation, and 
innate immunity. This was unexpected, as the degree of myocar-
dial necrosis in SCM is less than in AMI (7, 9). The trigger for this 
acute inflammatory response remains unclear.
Complement is an arm of the innate immune system that aids 
in the detection and clearance of self and bacterial antigens (27). 
It was demonstrated in 1990 that complement is activated in AMI 
(27). This is the first report of complement activation in SCM. 
Local hypoxia may play a role in complement activation and neu-
trophil chemoattraction to sites of ischemia (27). Complement 
activation can trigger endothelial adhesion molecule expression, 
TaBle 7 | KEGG pathway enrichment analysis: normal vs. stress 
cardiomyopathy.
Kegg pathway Proteins enrichment 
ratio
adj. 
p-value
Complement and coagulation 
cascades
C3, C4B, F2, A2M, F9, 
PLAT, F5
131.59 <0.001
Phagosome MLB2, C3, THBS2, 
ITGB3, ITGB1
37.09 <0.001
Dilated cardiomyopathy TNNI3, PRKACA, 
ITGB3, ITGB1
50.44 <0.001
Staphylococcus aureus 
infection
C3, C4B 61.90 <0.001
Focal adhesion THBS2, HGF, ITGB3, 
ITGB1
22.70 <0.001
Hypertrophic cardiomyopathy TNNI3, ITGB3, ITGB1 41.02 <0.001
ECM–receptor interaction THBS2, ITGB3, ITGB1 40.06 <0.001
Systemic lupus 
erythematosus
C3, C4B, ELANE 25.04 <0.01
Malaria HGF, THBS2 44.51 <0.01
Regulation of actin 
cytoskeleton
F2, ITGB3, ITGB1 15.98 <0.01
Arrhythmogenic right 
ventricular cardiomyopathy
ITGB3, ITGB1 30.67 <0.01
Leishmaniasis C3, ITGB1 31.53 <0.01
Pathways in cancer HGF, KLK3, ITGB1 10.44 <0.01
Axon guidance Netrin-1, ITGB1 17.60 <0.05
Wnt signaling pathway SFRP1, PRKACA 15.30 <0.05
Alzheimer’s disease APOE, GAPDH 13.59 <0.05
KEGG, Kyoto Encyclopedia of Genes and Genomes.
TaBle 6 | KEGG pathway enrichment analysis: normal vs. acute myocardial 
infarction.
Kegg pathway Proteins enrichment 
ratio
adj. 
p-value
Complement and 
coagulation cascades
C4B, C3, FGG, F2, F9, 
A2M
150.87 <0.001
Staphylococcus aureus 
infection
MBL2, C4B, C3, FGG 108.16 <0.001
Leshmaniasis C3, PTPN6, ITGB1 61.96 <0.001
Dilated Cardiomyopathy TNNI3, PRKACA, ITGB1 49.57 <0.001
Phagosome MBL2, C3, ITGB1 29.16 <0.001
Pathways in cancer HGF, KLK3, ITGB1 13.69 <0.05
Hypertrophic 
cardiomyopathy
TNNI3, ITGB1 35.83 <0.05
Systemic lupus 
erythematosus
C3, C4B 21.87 <0.05
Alzheimer’s disease APOE, GAPDH 17.81 <0.05
KEGG, Kyoto Encyclopedia of Genes and Genomes.
FigUre 3 | SOMAscan measured troponin correlates well with hospital-
based measurement. There was a strong and significant correlation between 
peak troponin I (TnI) (ng/ml) measured in the hospital laboratory and the TnI 
[relative fluorescent units (RFU)] as measured by SOMAscan. Open circles 
represent peak TnI in stress cardiomyopathy (SCM) patients (n = 15) and 
black triangles represent peak TnI in acute myocardial infarction (AMI) 
patients (n = 12).
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and subsequent leukocyte rolling, arrest, and diapedesis. It is 
notable that there are several small studies indicating that patients 
with SCM have greater endothelial dysfunction than those with 
AMI even in the subacute phase (28–30). This dysfunction could 
be due to low-level complement activation, increased leukocyte 
adhesion, and release of reactive oxygen species.
Complement is known to interact with the coagulation 
cascade (27). The increased levels of coagulation factor V (F5) 
and tissue plasminogen activator (PLAT, tPA) in SCM indicate 
that a pro-thrombotic state may be present. Patients with SCM 
have inducible hyperviscosity and there are multiple reports of 
increased thromboembolic events in the acute phase of SCM 
(31–33).
Several candidate proteins demonstrated a non-significant 
trend to be increased in acute SCM compared to AMI and 
controls [NET1, FSTL3, kallikrein 7 (KLK7), KYNU] (Figure 1, 
cluster 3). Netrin-1 is a neuronal growth factor that was originally 
reported in 1991 (34). NET1 promotes endothelial cell nitric 
oxide production and cell growth and migration in vitro via the 
receptor deleted in colorectal cancer (DCC) (35). NET1 has also 
been shown to reduce infarct size in mice (36). There is interest 
in using NET1 for the treatment of postischemic conditioning 
in AMI.
Follistatin-like 3 (FSTL3) was increased in SCM compared 
to controls. FSTL3 inhibits transforming growth factor beta 
(TGFβ) signaling (37). FSTL3 is upregulated in the myocardium 
and endothelium of failing human hearts (38). Cardiac specific 
ablation of FSTL3 reduces cardiac hypertrophy and fibrosis in 
response to transverse aortic constriction (37). FSTL3 may 
contribute to myocyte hypertrophy in response to stress stimuli, 
and the increased levels of FSTL3 in SCM may promote cardiac 
hypertrophy and fibrosis. This is consistent with prior data dem-
onstrating that SCM has a matrix metalloproteinase (MMP)/tis-
sue inhibitor of matrix metalloproteinase (TIMP) profile similar 
to hypertensive heart disease, which is distinct from AMI (26). 
We observed the same MMP/TIMP profile in our study (data 
not shown); however, the differences did not reach statistical 
significance. This is likely because the prior study used ELISA to 
measure MMP/TIMPs (26).
Kynureninase is an enzyme involved in tryptophan metabo-
lism. It degrades 3-hydroxy kynurenine to 3-hydroxyanthranillic 
acid (39). Kynurenine is an endothelium-derived relaxation fac-
tor induced in sepsis (40). Whether or not KYNU is truly elevated 
in SCM will be the topic of future studies. Finally, KLK7 is a serine 
proteinase belonging to the human kallikrein gene family, of 
which there are 15 members (41). The kallikrein system is broadly 
8Fitzgibbons et al. Acute Inflammation in SCM
Frontiers in Cardiovascular Medicine | www.frontiersin.org August 2017 | Volume 4 | Article 49
expressed and has also been demonstrated to play a role in cardiac 
remodeling (42).
limitations
We acknowledge that our study has a small sample size and 
this may lead to false negative results. The AMI group included 
patients with both infarction and ischemia; this led to a large SD 
in the peak TnI value for the AMI group (Table 1). Differences in 
medications given during the hospital stay may have influenced 
our results, in particular, the administration of heparin (17). 
The majority of our study participants were Caucasian women; 
therefore, the applicability of other races is limited. Many of our 
patients are referred from outside hospitals and were not available 
for the follow-up blood draw and echocardiogram. Unfortunately, 
we could not run the SOMAscan on all our samples due to cost 
limitations. Despite these limitations, we feel that our observa-
tions are original and make an important contribution to the 
literature.
cOnclUsiOn
In summary, despite different pathophysiologic mechanisms, 
the circulating proteome of AMI and SCM is similar. Activation 
of complement and coagulation pathways in SCM has not been 
previously reported and highlights the pro-thrombotic and 
inflammatory state of acute SCM. The stimulus for inflammation 
in SCM is unclear and will be the subject of future investigation. 
NET1, FSTL3, and KYNU, and KLK7 are putative markers of 
SCM that require prospective validation.
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